Drug Search Results
More Filters [+]

IkT-148x

Alternative Names: IkT-148x, IkT148x, IkT 148x
Latest Update: 2023-05-02
Latest Update Note: Clinical Trial Update

Product Description

Inhibikase is developing IKT148X, a small molecule c-Abl for the treatment of Multiple System Atrophy & Dementia with Lewy Body. (Sourced from: https://www.inhibikase.com/pipeline)

Mechanisms of Action: CABL Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Inhibikase Therapeutics
Company Location: ATLANTA GA 30339
Company CEO: Milton H. Werner
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IkT-148x

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Lewy Body Dementia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title